港股異動丨上海醫藥AH股齊升 去年淨利同比增13.28% 營收突破2千億
格隆匯3月31日丨上海醫藥H股漲2.61%報15.7港元,A股漲超5%報25.29元,公司2021年錄得股東應占溢利50.93億元,同比增長13.28%。擬每10股派發現金紅利4.2元。收入更是突破2000億元達到2158.24億元,同比增長12.46%。期內公司新獲18個進口新藥的總代資格,進口疫苗代理業務也實現銷售收入約43億元。上海醫藥此前孵化的兩個“互聯網+”平台——上藥雲健康和鎂信健康業務也在過去一年進展迅速,並分別啟動了上市進程。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.